For millions of older adults prescribed gabapentin or pregabalin for nerve pain, epilepsy, or anxiety, the assumed causal link between these drugs and broken bones may need fundamental reexamination. A prevailing clinical concern has been that gabapentinoids — by inducing sedation and dizziness — directly cause falls and fractures, sometimes prompting prescribers to withhold pain relief from already-vulnerable patients. This multinational evidence challenges that assumption in a clinically important way.
This large population-based study tracked fracture rates across multiple countries in older adults initiating gabapentinoid therapy. The defining finding is temporal: fracture incidence was highest in the window immediately preceding treatment initiation and decreased after gabapentinoids were started. This pattern — known in pharmacoepidemiology as a "protopathic bias" signal — suggests that the underlying conditions driving the prescription (pain, neurological instability, poor balance, opioid co-use) are themselves the dominant fracture drivers, not the gabapentinoid per se. The study also found that concurrent use of opioids or benzodiazepines substantially amplified fracture risk, pointing to polypharmacy as the true hazard.
This finding carries meaningful implications for how clinicians and patients weigh benefit versus risk. The gabapentinoid fracture concern has been embedded in prescribing guidelines and drug safety communications for years, sometimes functioning as a deterrent to adequate pain management in older populations who may benefit most. While this study does not eliminate the possibility of short-term fall risk around initiation — and preventive measures around that transition period remain sensible — the sustained causal narrative appears epidemiologically weak. The multinational design strengthens generalizability, though observational methodology cannot fully rule out residual confounding. Crucially, the polypharmacy signal reinforces a broader message: sedating medication combinations, not single agents, represent the more actionable fracture-prevention target in geriatric care.